News Archives - Page 91 of 93

FridayJun 10, 2022 4:02 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Robot Roadshow to Take the Spotlight at Kennedy Space Center

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that its Robot Roadshow will land in Florida at the Kennedy Space Center from 10 a.m. to 2 p.m. ET on June 17, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion. The announcement reads, “The Robot Roadshow has completed 45 landings in 16 states and Washington, D.C. to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience…

FridayJun 10, 2022 12:40 pm

TinyGemsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Completion of Key Milestones Position It for Success

Flora Growth Corp. (NASDAQ: FLGC) recently announced financial and operating results for the 2021 fiscal year that show the success of its efforts as revenues and profits begin what is expected to be a rapid climb. “The year-end financial results show about $9 million in revenues, which is ‘significantly higher’ than those reported the prior year before the law change and Flora’s IPO launch on the Nasdaq Capital Market. The report maintains the company’s outlook for ending 2022 with revenues of $35 million to $45 million, which would be growth of between 288% and 400% over 2021. Much of Flora’s…

FridayJun 10, 2022 10:48 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”). Cybin applied for IRB approval just last month. According to the announcement, Cybin wholly owned subsidiary Cybin IRL Limited has partnered with Clinilabs Drug Development Corporation to conduct the randomized, double-blind, placebo-controlled study. The study involves participants receiving two administrations of…

ThursdayJun 09, 2022 2:41 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise

Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs, and other outreach tools to generate greater awareness for Aditxt. “The potential market opportunities presented by immune monitoring and reprogramming are extensive. Through its work in the COVID-19 testing market with AditxtScore(TM), Aditxt demonstrated this potential. The company is now…

ThursdayJun 09, 2022 2:21 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX), Rogue Station Companies Inc./Everdime Inc. (RGST) Enter Partnership to Enhance Investor Communications

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has entered a partnership with Rogue Station Companies/Everdime (OTC: RGST). Through SRAX, RGST, a crypto and blockchain development company building the technology bridge that connects what is real and the new augmented reality within the metaverse, will have the ability to further reach its community through sophisticated solutions. “The RGST/Everdime team warmly welcomes our recent partnership with SRAX,” said RGST CEO Sandor Miklos. “As our company continues BETA testing its apps and prepares to launch its token and…

ThursdayJun 09, 2022 2:11 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.…

WednesdayJun 08, 2022 12:16 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

WednesdayJun 08, 2022 11:59 am

TinyGemsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Upcoming Event to Highlight Prominent Names and Companies in Decentralized Web Space

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that the Sequire Decentralized Web Conference will take place on June 23, 2022. As blockchain, DAOs, NFTS and digital currencies take off around the world with far-reaching potential, SRAX is bringing together a list of influential companies making history in this sector for a full day of presentations. Nearly nine million active small-cap investors were invited to the event, which will feature over 15 decentralized web focused companies and keynotes highlighting prominent names in this space.…

TuesdayJun 07, 2022 11:02 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

TuesdayJun 07, 2022 10:08 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News